United States Biotechnology & Medical Research

Transcode Therapeutics Inc (RNAZ)

Track

Transcode Therapeutics Inc has recorded no insider trading activity within the last three months. The most recent transactions occurred on September 28, 2023, when the Chief Executive Officer and Chief Financial Officer both executed buy orders. Prior to this, multiple purchase transactions were reported by company executives throughout 2022 and 2023.
Ticker: RNAZ Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Transcode Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.5
Fitzgerald Thomas A Chief Financial Officer Executive Director
Transaction date
Purchase
Price
410.95
Quantity 37,988 +6.0%
Value US$2,231,891
1.5
Dudley Robert Michael Chief Executive Officer Executive Director
Transaction date
Purchase
Price
34.49
Quantity 3,860 -26.9%
Value US$2,147,934
1.5
Dudley Robert Michael Chief Executive Officer Executive Director
Transaction date
Purchase
Price
390.03
Quantity 34,025 -43.4%
Value US$2,095,094
1.5
Dudley Robert Michael Chief Executive Officer Executive Director
Transaction date
Purchase
Price
2.55
Quantity 6,607 +10.4%
Value US$16,847
1.5
Dudley Robert Michael Chief Executive Officer Executive Director
Transaction date
Purchase
Price
2.76
Quantity 19,000 +2.1%
Value US$52,440
1.5
Dudley Robert Michael Chief Executive Officer Executive Director Large shareholder
Transaction date
Purchase
Price
1.15
Quantity 20,000 +2.3%
Value US$23,000
1.5
Fitzgerald Thomas A Chief Financial Officer Executive Director
Transaction date
Purchase
Price
1.27
Quantity 12,000 +9.4%
Value US$15,240
1.5
Dudley Robert Michael Chief Executive Officer Executive Director Large shareholder
Transaction date
Purchase
Price
1.87
Quantity 2,000 +0.2%
Value US$3,740
1.5
Dudley Robert Michael Chief Executive Officer Executive Director Large shareholder
Transaction date
Purchase
Price
1.84
Quantity 28,000 +3.3%
Value US$51,643
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-10-02 2023-09-28 B Purchase
1.5
Fitzgerald Thomas A

Chief Financial Officer

Executive Director
37,988 +6.0%
410.95
US$2,231,891 		37,988 +6.0% 410.95 US$2,231,891
2023-10-02 2023-09-28 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director
3,860 -26.9%
34.49
US$2,147,934 		3,860 -26.9% 34.49 US$2,147,934
2023-06-22 2023-06-21 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director
34,025 -43.4%
390.03
US$2,095,094 		34,025 -43.4% 390.03 US$2,095,094
2023-06-22 2023-06-20 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director
6,607 +10.4%
2.55
US$16,847 		6,607 +10.4% 2.55 US$16,847
2023-06-13 2023-06-09 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director
19,000 +2.1%
2.76
US$52,440 		19,000 +2.1% 2.76 US$52,440
2022-09-16 2022-09-14 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director Large shareholder
20,000 +2.3%
1.15
US$23,000 		20,000 +2.3% 1.15 US$23,000
2022-06-17 2022-06-16 B Purchase
1.5
Fitzgerald Thomas A

Chief Financial Officer

Executive Director
12,000 +9.4%
1.27
US$15,240 		12,000 +9.4% 1.27 US$15,240
2022-06-01 2022-05-31 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director Large shareholder
2,000 +0.2%
1.87
US$3,740 		2,000 +0.2% 1.87 US$3,740
2022-06-01 2022-05-27 B Purchase
1.5
Dudley Robert Michael

Chief Executive Officer

Executive Director Large shareholder
28,000 +3.3%
1.84
US$51,643 		28,000 +3.3% 1.84 US$51,643
Explore more

More insider trading research around Transcode Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America